Page last updated: 2024-12-11

pepstatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pepstatin: inhibits the aspartic protease endothiapepsin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5478883
CHEMBL ID296588
CHEBI ID7989
SCHEMBL ID50324
SCHEMBL ID19469525
MeSH IDM0098629

Synonyms (120)

Synonym
(3s,4s)-3-hydroxy-4-[(2s)-2-[(3s,4s)-3-hydroxy-6-methyl-4-[(2s)-3-methyl-2-[(2s)-3-methyl-2-(3-methylbutanamido)butanamido]butanamido]heptanamido]propanamido]-6-methylheptanoic acid
bdbm912
chembl296588 ,
BRD-K13571841-001-03-7
MLS000069747
smr000059191
D03818
pepstatin (usan/inn)
procidin s 735a
l-alaninamide, n-(3-methyl-1-oxobutyl)-l-valyl-(3s,4s)-4-amino-3-hydroxy-6-methylheptanoyl-n-((1s)-1-((1s)-2-carboxy-1-hydroxyethyl)-3-methylbutyl)-
pepstatina [inn-spanish]
heptanoic acid, n-(3-methyl-1-oxobutyl)-l-valyl-l-valyl-(3s,4s)-3-hydroxy-6-methyl-4-aminoheptanoyl-l-alanyl-(3s,4s)-3-hydroxy-6-methyl-4-amino-
nsc 272671
l-valinamide, n-(3-methyl-1-oxobutyl)-l-valyl-n-(4-((2-((1-(2-carboxy-1-hydroxyethyl)-3-methylbutyl)amino)-1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl)-, (1s-(1r*,2r*,4(r*(r*(r*)))))-
pepstatinum [inn-latin]
n-isovaleryl-l-valyl-l-valyl-3-hydroxy-6-methyl-gamma-aminoheptanoyl-l-alanyl-3-hydroxy-6-methyl-gamma-aminoheptanoic acid
pepsin inhibitor s 735a
pepstatin [usan:inn]
einecs 247-600-0
brn 2201362
pepstatine [inn-french]
cas-26305-03-3
BIO2_000340
BIO1_000893
BIO1_000404
BIO2_000820
BIO1_001382
IDI1_002095
pepstatin a ,
n-(3-methyl-1-oxobutyl)-l-valyl-l-valyl-4-amino-3-hydroxy-6-methylheptanoyl-l-alanyl-4-amino-3-hydroxy-6-methylheptanoic acid
nsc-272671
BPBIO1_000364
BSPBIO_001000
BSPBIO_000330
(3s,4s)-3-hydroxy-4-[[(2s)-2-[[(3s,4s)-3-hydroxy-6-methyl-4-[[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanoyl]amino]propanoyl]amino]-6-methyl-heptanoic acid
pepstatine
n-[(3-methyl-1-oxobutyl)-l-valyl-l-valyl-4-amino-3-hydroxy-6-methylheptanoyl-l-alanyl]-4-amino-3-hydroxy-6-methylheptanoic acid
iva-val-val-sta-ala-sta-oh
UPCMLD-DP141:001
AB00513830
pepstatin
26305-03-3
pepstatin a, microbial, >=90% (hplc)
pepstatin a, microbial, >=75% (hplc)
UPCMLD-DP141
6APR
1LYB
4ER2
1SME
UPCMLD-DP141:002
NCGC00161670-02
NCGC00161670-01
pepstatin (nonspecific)
pepstatin (van)
ahpatinin c
ccris 3603
c34h63n5o9
KBIO2_000340
KBIOSS_000340
KBIO3_000680
KBIOGR_000340
KBIO2_005476
KBIO3_000679
KBIO2_002908
PRESTWICK3_000405
NCGC00161670-03
NCGC00161670-04
NCGC00160128-02
39324-30-6
pepstatin a, >=100,000 u/mg
HMS1990B21
MLS002222329 ,
smr001307268
HMS1792B21
HMS1362B21
MLS002207302
(3s,4s)-3-hydroxy-4-[[(2s)-2-[[(3s,4s)-3-hydroxy-6-methyl-4-[[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanoyl]amino]propanoyl]amino]-6-methylheptanoic acid
3-hydroxy-4-[2-[[3-hydroxy-6-methyl-4-[[3-methyl-2-[[3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanoyl]amino]propanoylamino]-6-methylheptanoic acid
HMS2096A12
tox21_111747
dtxsid7046095 ,
dtxcid5026095
pepstatinum
pepstatina
unii-v6y2t27q1u
v6y2t27q1u ,
HMS2233I07
S7381
pepstatin [mi]
pepstatin [inn]
pepstatin [usan]
pepstatin [who-dd]
CCG-207852
SCHEMBL50324
MLS006010748
NCGC00161670-06
tox21_111747_1
CS-4202
n-(3-methylbutanoyl)-l-valyl-n-[(3s,4s)-1-{[(2s)-1-{[(2s,3s)-1-carboxy-2-hydroxy-5-methylhexan-3-yl]amino}-1-oxopropan-2-yl]amino}-3-hydroxy-6-methyl-1-oxoheptan-4-yl]-l-valinamide
CHEBI:7989
l-alaninamide, n-(3-methyl-1-oxobutyl)-l-valyl-l-valyl-(3s,4s)-4-amino-3-hydroxy-6-methylheptanoyl-n-[(1s)-1-[(1s)-2-carboxy-1-hydroxyethyl]-3-methylbutyl]-
HB3359
HY-P0018
AKOS024456453
HMS3403B21
SCHEMBL19469525
AC-8820
SR-01000721876-3
sr-01000721876
pepstatin, from streptomyces species
HMS3713A12
(6s,9s,12s,13s,17s,20s,21s)-13,21-dihydroxy-12,20-diisobutyl-6,9-diisopropyl-2,17-dimethyl-4,7,10,15,18-pentaoxo-5,8,11,16,19-pentaazatricosan-23-oic acid
pepstatin a; isovaleryl-val-val-sta-ala-sta-oh
BCP15859
BS-16753
EX-A4027
Q7166509
C74361
isovaleryl-val-val-4-amino-3-hydroxy-6-methylheptanoyl-ala-4-amino-3-hydroxy-6-methylheptanoic acid
iva-val-val-sta-ala-sta

Research Excerpts

Overview

Pepstatin could protect patients against reflux tonsil hypertrophy by inhibiting pepsin. Pepstatin is a potent peptidyl inhibitor of various malarial aspartic proteases, and also has parasiticidal activity.

ExcerptReferenceRelevance
"Pepstatin is a potent inhibitor of pepsin activity and could protect patients against reflux tonsil hypertrophy by inhibiting pepsin."( Effects of pepsin and pepstatin on reflux tonsil hypertrophy in vitro.
Jang, SJ; Jung, MH; Kim, JH; Woo, SH; Yun, JW, 2018
)
1.52
"Pepstatin is a potent peptidyl inhibitor of various malarial aspartic proteases, and also has parasiticidal activity. "( Esterase mutation is a mechanism of resistance to antimalarial compounds.
Corey, VC; Dharia, NV; Goldberg, DE; Istvan, ES; Mallari, JP; Marshall, GR; Winzeler, EA, 2017
)
1.9
"Pepstatin A was found to be an effective agent to block angiotensin I generation during the RIA, and the sample can be directly incubated at room temperature for RIA without any special treatment to inhibit renin activity."( Measurement of plasma renin activity by a simple solid phase radioimmunoassay.
Iinuma, K; Ikeda, I; Kumahara, Y; Kurata, K; Ogihara, T; Takai, M; Yanagawa, Y, 1982
)
0.99
"Pepstatin is a slow and tight-binding inhibitor of pepsin. "( Solvent isotope effects on the onset of inhibition of porcine pepsin by pepstatin.
Cho, YK; Northrop, DB; Rebholz, KL, 1994
)
1.96
"Pepstatin is a specific inhibitor of keratinolytic proteinase (KPase) from C."( A specific inhibitor of keratinolytic proteinase from Candida albicans could inhibit the cell growth of C. albicans.
Kurita, Y; Negi, M; Ogawa, H; Tsuobi, R, 1985
)
0.99

Effects

ExcerptReferenceRelevance
"Pepstatin A has an extended conformation to the P'2 alanine residue, but the leucyl side chain of the terminal statine residue binds back into the S'1 subsite, and an inverse gamma-turn occurs between P'1 and P'3."( X-ray-crystallographic studies of complexes of pepstatin A and a statine-containing human renin inhibitor with endothiapepsin.
Atrash, B; Bailey, D; Blundell, TL; Cooper, JB; Jones, DM; Szelke, M; Veerapandian, B, 1993
)
1.26
"Pepstatin A has an extended conformation to the P'2 alanine residue, but the leucyl side chain of the terminal statine residue binds back into the S'1 subsite, and an inverse gamma-turn occurs between P'1 and P'3."( X-ray-crystallographic studies of complexes of pepstatin A and a statine-containing human renin inhibitor with endothiapepsin.
Atrash, B; Bailey, D; Blundell, TL; Cooper, JB; Jones, DM; Szelke, M; Veerapandian, B, 1993
)
1.26

Actions

ExcerptReferenceRelevance
"Pepstatin A was able to inhibit the growth of conidium and its transformation into mycelium."( Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.
Alviano, CS; dos Santos, AL; Kneipp, LF; Palmeira, VF, 2006
)
1.06

Treatment

Pepstatin-treated mice showed amyloid deposition significantly sooner than the control group, which had received only casein. Pepstatin A pretreatment did not prevent release of cathepsin D from lysosomes but did significantly inhibit subsequent naphthazarin-induced caspase activation.

ExcerptReferenceRelevance
"Pepstatin A treatment slowed interstitial fibrosis progression following IRI induced AKI."( Lysosomal protease cathepsin D; a new driver of apoptosis during acute kidney injury.
Cocchiaro, P; Fox, C; Howarth, R; Moles, A; Pavone, LM; Sheerin, NS; Situmorang, GR; Tregidgo, NW; Wood, KM, 2016
)
1.16
"Pepstatin-treated mice showed amyloid deposition significantly sooner than the control group, which had received only casein."( Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin.
Benson, MD; Kluve-Beckerman, B; Liepnieks, J; Yamada, T, 1996
)
1.24
"Pepstatin A pretreatment did not prevent release of cathepsin D from lysosomes but did significantly inhibit subsequent naphthazarin-induced caspase activation and apoptotic morphology."( Inhibition of cathepsin D prevents free-radical-induced apoptosis in rat cardiomyocytes.
Ollinger, K, 2000
)
1.03
"Treatment with pepstatin A did not change the effect of C."( Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans.
Frank, CF; Hostetter, MK, 2007
)
0.68

Bioavailability

ExcerptReferenceRelevance
" We conclude that (1) pepstatin is a potent but poorly bioavailable antimalarial; (2) PfPARE is a functional esterase that is capable of activating prodrugs; (3) Mutations in PfPARE constitute a mechanism of antimalarial resistance."( Esterase mutation is a mechanism of resistance to antimalarial compounds.
Corey, VC; Dharia, NV; Goldberg, DE; Istvan, ES; Mallari, JP; Marshall, GR; Winzeler, EA, 2017
)
0.77
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" We found that saralasin or DuP 753, but not the kinin antagonist, displaced the dose-response curve to the right."( Oxytocic effect of trypsin on the isolated rat uterus.
Castillo, G; Esteban, S; Orce, G, 1994
)
0.29
" It was used Pepstatin as a model inhibitor of Plasmepsin II and the resulting dose-response relation agreed with the expected behavior for the Pepstatin-Plasmepsin II pair under the employed experimental conditions."( A heterogeneous enzymatic assay for quantification of Plasmepsin II activity and the evaluation of its inhibitors.
Chávez, MA; Duarte, CA; Gutiérrez, OA; Mendiola, J; Otero-Bilbao, A; Otero-González, A; Ramírez, A; Reyes, O; Salas, E; Vázquez, R, 2004
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
EC 3.4.23.* (aspartic endopeptidase) inhibitorAn EC 3.4.* (hydrolases acting on peptide bond) inhibitor that interferes with the action of any aspartic endopeptidase (EC 3.4.23.*).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pentapeptideAny molecule that contains five amino-acid residues connected by peptide linkages.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
thyroid hormone biosynthesis524
hemoglobin degradation107

Protein Targets (44)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency79.43280.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency31.62280.125919.1169125.8920AID2549
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
regulator of G-protein signaling 4Homo sapiens (human)Potency5.97280.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency2.09310.001310.157742.8575AID1259256
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.25120.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
heat shock protein beta-1Homo sapiens (human)Potency0.84120.042027.378961.6448AID743210
gemininHomo sapiens (human)Potency0.51740.004611.374133.4983AID624296
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.79680.251215.843239.8107AID504327
TAR DNA-binding protein 43Homo sapiens (human)Potency0.35481.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency5.35820.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CATHEPSIN DHomo sapiens (human)Ki0.00000.00000.00000.0000AID977610
Chain B, CATHEPSIN DHomo sapiens (human)Ki0.00000.00000.00000.0000AID977610
Chain A, PLASMEPSIN IIPlasmodium falciparum (malaria parasite P. falciparum)Ki0.00000.00000.00000.0000AID977610
Chain E, ENDOTHIAPEPSINCryphonectria parasitica (chestnut blight fungus)Ki0.00050.00050.00050.0005AID977610
Chain E, RHIZOPUSPEPSINRhizopus microsporus var. chinensisKi0.01700.01700.01700.0170AID977610
Chain E, ENDOTHIAPEPSINCryphonectria parasitica (chestnut blight fungus)Ki0.00050.00050.00050.0005AID977610
Chain E, ENDOTHIAPEPSINCryphonectria parasitica (chestnut blight fungus)Ki0.00050.00050.00050.0005AID977610
Chain E, RHIZOPUSPEPSINRhizopus microsporus var. chinensisKi0.01700.01700.01700.0170AID977610
Chain E, RHIZOPUSPEPSINRhizopus microsporus var. chinensisKi0.01700.01700.01700.0170AID977610
Pepsin ASus scrofa (pig)IC50 (µMol)0.01100.00702.15078.2000AID156723; AID156724; AID156725; AID156733; AID156736
Pepsin ASus scrofa (pig)Ki0.00000.00000.00000.0001AID156757; AID156765
ReninHomo sapiens (human)IC50 (µMol)44.44290.00000.77968.2000AID195626; AID198674; AID198676; AID198696
ReninHomo sapiens (human)Ki6.55000.00001.80787.4000AID198994; AID198995
Cathepsin DHomo sapiens (human)IC50 (µMol)5.89530.00000.931610.0000AID1186403; AID1305441; AID1355752; AID1493086; AID1493087; AID1493092; AID1493094; AID1529188; AID1701377; AID1901890; AID271447; AID331709; AID350740; AID448176; AID448183; AID448188; AID48010; AID711207
Cathepsin DHomo sapiens (human)Ki0.00000.00000.00120.0020AID48026
Procathepsin LHomo sapiens (human)IC50 (µMol)0.80000.00021.66619.5100AID350738
Cathepsin BHomo sapiens (human)IC50 (µMol)4.26000.00021.845310.0000AID350737
Pro-cathepsin HHomo sapiens (human)IC50 (µMol)100.00000.12592.740410.0000AID350739
Candidapepsin-2Candida albicansIC50 (µMol)0.09000.09000.09000.0900AID718212
Pepsin A-5Homo sapiens (human)IC50 (µMol)0.05900.05900.05900.0590AID156895
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)Ki3.10000.00000.12203.1000AID1795283
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)100.00000.00001.612910.0000AID37935
Cathepsin EHomo sapiens (human)IC50 (µMol)0.55580.00011.376610.0000AID1186404; AID1305442; AID1493088; AID1493093; AID1493095; AID1493096; AID1901891; AID448177; AID448184; AID448189; AID711206
Plasmepsin-1Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.00090.00090.14050.2800AID1391981
Plasmepsin-2Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.00050.00040.69632.4000AID1391982; AID331710
Cathepsin D Bos taurus (cattle)IC50 (µMol)0.02350.00700.91656.3000AID47824; AID47827; AID47838; AID47843
Cathepsin D Bos taurus (cattle)Ki0.00050.00050.00050.0005AID47998
Disintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)IC50 (µMol)0.05630.00102.528410.0000AID448178
Plasmepsin 4 Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.00030.00030.00030.0003AID1391983
Protease Human immunodeficiency virus 1Ki1.18670.00000.04433.1000AID1189199; AID160613; AID160617; AID160777
Cysteine proteaseLeishmania donovaniIC50 (µMol)0.16000.01000.08500.1600AID282104
TransporterRattus norvegicus (Norway rat)Ki36.50000.00010.866710.0000AID239204
Protease Human immunodeficiency virus 1IC50 (µMol)0.94700.00000.81769.8500AID340320; AID351540; AID415648
Protease Human immunodeficiency virus 1Ki0.18240.00000.02841.1000AID1067634; AID1067635; AID1067636; AID1189198; AID351541; AID351542; AID351543; AID397608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cathepsin DHomo sapiens (human)INH0.00010.00010.00010.0001AID1917917
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (111)

Processvia Protein(s)Taxonomy
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
autophagosome assemblyCathepsin DHomo sapiens (human)
proteolysisCathepsin DHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin DHomo sapiens (human)
insulin receptor recyclingCathepsin DHomo sapiens (human)
lipoprotein catabolic processCathepsin DHomo sapiens (human)
positive regulation of apoptotic processCathepsin DHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCathepsin DHomo sapiens (human)
regulation of establishment of protein localizationCathepsin DHomo sapiens (human)
insulin catabolic processCathepsin DHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
metanephros developmentPro-cathepsin HHomo sapiens (human)
T cell mediated cytotoxicityPro-cathepsin HHomo sapiens (human)
adaptive immune responsePro-cathepsin HHomo sapiens (human)
immune response-regulating signaling pathwayPro-cathepsin HHomo sapiens (human)
proteolysisPro-cathepsin HHomo sapiens (human)
apoptotic processPro-cathepsin HHomo sapiens (human)
positive regulation of cell population proliferationPro-cathepsin HHomo sapiens (human)
positive regulation of gene expressionPro-cathepsin HHomo sapiens (human)
positive regulation of epithelial cell migrationPro-cathepsin HHomo sapiens (human)
neuropeptide catabolic processPro-cathepsin HHomo sapiens (human)
bradykinin catabolic processPro-cathepsin HHomo sapiens (human)
positive regulation of peptidase activityPro-cathepsin HHomo sapiens (human)
antigen processing and presentationPro-cathepsin HHomo sapiens (human)
positive regulation of cell migrationPro-cathepsin HHomo sapiens (human)
zymogen activationPro-cathepsin HHomo sapiens (human)
protein destabilizationPro-cathepsin HHomo sapiens (human)
response to retinoic acidPro-cathepsin HHomo sapiens (human)
membrane protein proteolysisPro-cathepsin HHomo sapiens (human)
negative regulation of apoptotic processPro-cathepsin HHomo sapiens (human)
surfactant homeostasisPro-cathepsin HHomo sapiens (human)
positive regulation of angiogenesisPro-cathepsin HHomo sapiens (human)
dichotomous subdivision of terminal units involved in lung branchingPro-cathepsin HHomo sapiens (human)
ERK1 and ERK2 cascadePro-cathepsin HHomo sapiens (human)
cellular response to thyroid hormone stimulusPro-cathepsin HHomo sapiens (human)
positive regulation of apoptotic signaling pathwayPro-cathepsin HHomo sapiens (human)
proteolysis involved in protein catabolic processPro-cathepsin HHomo sapiens (human)
immune responsePro-cathepsin HHomo sapiens (human)
digestionPepsin A-5Homo sapiens (human)
proteolysisPepsin A-5Homo sapiens (human)
proteolysisCathepsin EHomo sapiens (human)
protein autoprocessingCathepsin EHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin EHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of MAP kinase activityDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
membrane protein intracellular domain proteolysisDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell-matrix adhesionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
integrin-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to manganese ionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell migrationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
keratinocyte differentiationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell-cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of macrophage fusionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to tumor necrosis factorDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to laminar fluid shear stressDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
monocyte activationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to hydrogen peroxideDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of protein secretionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to glucocorticoidDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
positive regulation of keratinocyte migrationDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to calcium ionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cellular response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
response to antineoplastic agentDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
proteolysisChymotrypsin-CHomo sapiens (human)
intracellular calcium ion homeostasisChymotrypsin-CHomo sapiens (human)
proteolysisChymotrypsin-CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (35)

Processvia Protein(s)Taxonomy
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin DHomo sapiens (human)
protein bindingCathepsin DHomo sapiens (human)
peptidase activityCathepsin DHomo sapiens (human)
aspartic-type peptidase activityCathepsin DHomo sapiens (human)
aspartic-type endopeptidase activityCathepsin DHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
endopeptidase activityPro-cathepsin HHomo sapiens (human)
aminopeptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type endopeptidase activityPro-cathepsin HHomo sapiens (human)
serine-type endopeptidase activityPro-cathepsin HHomo sapiens (human)
protein bindingPro-cathepsin HHomo sapiens (human)
peptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type peptidase activityPro-cathepsin HHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processPro-cathepsin HHomo sapiens (human)
HLA-A specific activating MHC class I receptor activityPro-cathepsin HHomo sapiens (human)
thyroid hormone bindingPro-cathepsin HHomo sapiens (human)
aspartic-type endopeptidase activityPepsin A-5Homo sapiens (human)
aspartic-type endopeptidase activityCathepsin EHomo sapiens (human)
peptidase activityCathepsin EHomo sapiens (human)
identical protein bindingCathepsin EHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
protein kinase C bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
collagen bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
laminin bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
protein bindingChymotrypsin-CHomo sapiens (human)
peptidase activityChymotrypsin-CHomo sapiens (human)
serine-type endopeptidase activityChymotrypsin-CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (44)

Processvia Protein(s)Taxonomy
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
collagen-containing extracellular matrixCathepsin DHomo sapiens (human)
extracellular regionCathepsin DHomo sapiens (human)
extracellular spaceCathepsin DHomo sapiens (human)
lysosomeCathepsin DHomo sapiens (human)
lysosomal membraneCathepsin DHomo sapiens (human)
endosome membraneCathepsin DHomo sapiens (human)
endosome lumenCathepsin DHomo sapiens (human)
specific granule lumenCathepsin DHomo sapiens (human)
melanosomeCathepsin DHomo sapiens (human)
lysosomal lumenCathepsin DHomo sapiens (human)
membrane raftCathepsin DHomo sapiens (human)
collagen-containing extracellular matrixCathepsin DHomo sapiens (human)
extracellular exosomeCathepsin DHomo sapiens (human)
tertiary granule lumenCathepsin DHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin DHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
extracellular regionPro-cathepsin HHomo sapiens (human)
extracellular spacePro-cathepsin HHomo sapiens (human)
lysosomePro-cathepsin HHomo sapiens (human)
cytosolPro-cathepsin HHomo sapiens (human)
secretory granule lumenPro-cathepsin HHomo sapiens (human)
cytoplasmic ribonucleoprotein granulePro-cathepsin HHomo sapiens (human)
intracellular membrane-bounded organellePro-cathepsin HHomo sapiens (human)
collagen-containing extracellular matrixPro-cathepsin HHomo sapiens (human)
extracellular exosomePro-cathepsin HHomo sapiens (human)
alveolar lamellar bodyPro-cathepsin HHomo sapiens (human)
multivesicular body lumenPro-cathepsin HHomo sapiens (human)
tertiary granule lumenPro-cathepsin HHomo sapiens (human)
ficolin-1-rich granule lumenPro-cathepsin HHomo sapiens (human)
extracellular spacePro-cathepsin HHomo sapiens (human)
lysosomePro-cathepsin HHomo sapiens (human)
extracellular exosomePepsin A-5Homo sapiens (human)
multivesicular body lumenPepsin A-5Homo sapiens (human)
endosomeCathepsin EHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin EHomo sapiens (human)
endosomeCathepsin EHomo sapiens (human)
extracellular regionCathepsin D Bos taurus (cattle)
lysosomeCathepsin D Bos taurus (cattle)
melanosomeCathepsin D Bos taurus (cattle)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
extracellular spaceDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
external side of plasma membraneDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
basolateral plasma membraneDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
extracellular exosomeDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
extracellular spaceDisintegrin and metalloproteinase domain-containing protein 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (267)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID90869The compound was tested for inhibitory effect towards the pepsin hydrolysis of Horseradish peroxidase1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Simplified pepstatins: synthesis and evaluation of N-terminally modified analogues.
AID1917917Inhibition of cathepsin D (unknown origin) using MCA labelled GKPILFFRLK(Dnp)-D-R-NH as substrate preincubated for 15 mins followed by substrate addition and measured after 2 hrs by fluorometer analysis2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID462238Antifungal activity against Candida albicans SA40 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 14 after infection2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID198693Plasma renin inhibitory activity was evaluated in lyophilized human plasma with 0.1%EDTA1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors.
AID1493086Inhibition of secreted cathepsin D in human MDA-MB-231 cells using Mca-Gly-Lys-Pro-Ile-Leu-PhePhe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate pretreated for 3 days under pH 6.6 conditioned media followed by substrate addition measured at 5 mins interval for 2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID427588Inhibition of SAP9-dependent growth in Candida albicans SAP2MS4B expressing SAP9deltaC493 at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID480876Inhibition of Plasmodium falciparum plasmepsin-2 expressed in Escherichia coli BL21 (DE3) at 1 uM after 30 min by FRET assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
AID1493110Antimigratory activity against human MDA-MB-231 cells at 5 uM after 48 hrs by crystal violet staining based microscopic method relative to control2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID1493108Inhibition of cathepsin D in human MDA-MB-231 cells assessed as reduction in tPA residual activity at 10 uM incubated for 3 days under pH 6.6 conditioned media measured at 1 hr interval for 8 hrs by chromogenic method relative to control2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID239203Inhibitory binding affinity towards recombinant human T-cell leukemia virus type I (HTLV-1) protease2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
AID1355752Inhibition of human cathepsin D using GKPILFFRLK(DNP)-D-RNH2) labeled MCA as substrate preincubated for 10 mins followed by substrate addition measured after 1 to 2 hrs by fluorometric method2018Journal of natural products, 07-27, Volume: 81, Issue:7
Izenamides A and B, Statine-Containing Depsipeptides, and an Analogue from a Marine Cyanobacterium.
AID1740298Inhibition of recombinant Candida albicans SAP2 using Dabcyl-Arg-Lys-Pro-Ala-Leu-Phe-Phe-Arg-Leu-Glu (EDANS)-Arg-OH as substrate incubated for 30 mins followed by substrate addition and measured after 30 mins by spectrophotometry2020European journal of medicinal chemistry, Sep-01, Volume: 201Targeting fungal virulence factor by small molecules: Structure-based discovery of novel secreted aspartic protease 2 (SAP2) inhibitors.
AID1186403Inhibition of cathepsin D (unknown origin)2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Structure-based optimization of non-peptidic Cathepsin D inhibitors.
AID1493099Inhibition of human liver cathepsin D at 1 uM using recombinant PAI-1 as substrate measured after 3 hrs by silver staining based SDS-PAGE analysis2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID374060Antimalarial activity against chloroquine-sensitive Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) erythrocytes at 10 uM after 18 hrs as reduced hemoglobin hydrolysis2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis and antimalarial activity of pyrazolo and pyrimido benzothiazine dioxide derivatives.
AID1529191Cytotoxicity against NHDF cells assessed as reduction in cell viability up to 100 uM measured after 72 hrs by Celltiter-glo assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure-Activity Relationship and Binding Mode Analysis.
AID415648Inhibition of HIV1 protease by HPLC method2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Synthesis of dammarane-type triterpene derivatives and their ability to inhibit HIV and HCV proteases.
AID48026Binding affinity against human cathepsin D2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID243927Percent inhibition of synthesized human T-cell leukemia virus type I (HTLV-1) protease was determined at 50 uM concentration2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
AID1391982Inhibition of Plasmodium falciparum plasmepsin-2 using DABCYL-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-EDANS as substrate preincubated for 30 mins followed by substrate addition measured every 1 min within 8 to 15 mins by FRET assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity.
AID1067636Inhibition of HIV-1 recombinant protease using DABCYL-GABA-Ser-Asn-Tyr-Pro-Ile-Val-Gln-EDANS as substrate incubated for 30 mins prior to substrate addition by Lineweaver-Burk plot analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.
AID198994Inhibition of human kidney renin1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.
AID47998Inhibition of cathepsin D.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin.
AID1123540Inhibition of porcine pepsin activity assessed as hydrolysis of N-Cbz-L-Pheylalanyl-L-Tyrosine substrate1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of all the stereoisomers of statine (4-amino-3-hydroxy-6-methylheptanoic acid). Inhibition of pepsin activity by N-carbobenzoxy-L-valyl-L-valyl-statine derived from the four stereoisomers.
AID462258Antifungal activity against pharmacoresistant Candida albicans AIDS68 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 14 after in2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID462240Antifungal activity against Candida albicans SA40 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 5 after infection2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID397606Antiviral activity against HIV1 RF in human CEM cells2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID718212Inhibition of candida albicans SAP2 using 0.05% BSA as substrate by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype.
AID581964Antimicrobial activity against wild type Plasmodium falciparum HB3 infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID225412In vitro inhibitory activity against man (human) plasma renin1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Pepstatin analogues as novel renin inhibitors.
AID156723Inhibition of porcine pepsin1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.
AID397590Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID225410In vitro inhibitory activity against dog plasma renin1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Pepstatin analogues as novel renin inhibitors.
AID711207Inhibition of cathepsin D by fluorescence assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases.
AID225414In vitro inhibitory activity against rat plasma renin1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Pepstatin analogues as novel renin inhibitors.
AID711206Inhibition of cathepsin E by fluorescence assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases.
AID1493107Inhibition of cathepsin D in human MDA-MB-231 cells assessed as reduction in tPA residual activity at 100 uM incubated for 3 days under pH 6.6 conditioned media measured at 1 hr interval for 8 hrs by chromogenic method relative to control2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID156725Compound was tested for inhibition of porcine pepsin1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues.
AID1409607IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1493098Inhibition of human liver cathepsin D at 1 uM using recombinant human cystatin-C as substrate measured after 3 hrs by silver staining based SDS-PAGE analysis2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID1067635Inhibition of HIV-1 recombinant protease using DABCYL-GABA-Ser-Asn-Tyr-Pro-Ile-Val-Gln-EDANS as substrate incubated for 30 mins prior to substrate addition by Hanes plot analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.
AID350738Inhibition of human liver cathepsin L after 30 mins by fluorometric end-point assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity.
AID462225Antifungal activity against pharmacoresistant Candida albicans AIDS68 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 24 hrs after fungal infection measured on day 2 after inf2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID47843Tested for inhibition of Cathepsin D from bovine1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
AID52471Tested for inhibition of Chymotrypsinogen from bovine1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
AID351543Inhibition of HIV1 protease by Dixon method2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
On the inhibition of HIV-1 protease by hydrazino-ureas displaying the N-->C=O interaction.
AID160617The compound was tested for its affinity against HIV-1 protease; range 400-1400 nM1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
HIV protease: a novel chemotherapeutic target for AIDS.
AID1243951Inhibition of recombinant HIV1 protease at 2 uM using FRET substrate peptide by FRET assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods.
AID1184415Inhibition of HIV-1 protease using DABCYL-Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS as substrate preincubated at 10 uM for 15 mins before substrate addition measured over 15 mins by fluorometric assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors.
AID331710Inhibition of Plasmodium falciparum plasmepsin-2 by FRET assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
AID1901890Inhibition of recombinant human liver Cathepsin D using Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate incubated for 120 mins by fluorescence assay2022Bioorganic & medicinal chemistry, 03-01, Volume: 57Cathepsin D inhibitors based on tasiamide B derivatives with cell membrane permeability.
AID366497Inhibition of recombinant hemoglobinase 22008Journal of natural products, Aug, Volume: 71, Issue:8
Prenylated dihydrochalcones from Boronia bipinnata that inhibit the malarial parasite enzyme target hemoglobinase II.
AID357298Inhibition of Candida albicans secreted aspartic protease2001Journal of natural products, Aug, Volume: 64, Issue:8
New indole alkaloids from the bark of Nauclea orientalis.
AID448184Inhibition of cathepsin E in human MCF7 cells by fluorescence assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID243849Percent inhibition of human immunodeficiency virus type I (HIV-1) protease was determined at 50 uM concentration2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
AID198995Antihypertensive activity against human renin1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension.
AID198479Inhibition of human plasma renin1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues.
AID198674Inhibition of human renin1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.
AID1391983Inhibition of Plasmodium falciparum plasmepsin 4 using DABCYL-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-EDANS as substrate preincubated for 30 mins followed by substrate addition measured every 1 min within 8 to 15 mins by FRET assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity.
AID462260Antifungal activity against pharmacoresistant Candida albicans AIDS68 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 28 after in2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID480880Inhibition of Plasmodium falciparum plasmepsin-2 expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 1 uM measured after overnight dialysis by spun column chromatography2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
AID1493101Inhibition of cathepsin D in human MDA-MB-231 cells assessed as reduction in cysteine cathepsin activity at 1 to 10 uM using Z-Phe-Arg-AMC as substrate pretreated for 3 days under pH 6.6 conditioned media followed by substrate addition measured at 5 mins 2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID448186Selectivity ratio of IC50 for cathepsin E in human MCF7 cells to IC50 for cathepsin E2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID357964Inhibition of pepsin2001Journal of natural products, Oct, Volume: 64, Issue:10
Phenolic compounds from Miconia myriantha inhibiting Candida aspartic proteases.
AID1493087Inhibition of human liver cathepsin D using Mca-Gly-Lys-Pro-Ile-Leu-PhePhe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate pretreated for 15 mins followed by substrate addition measured at 5 mins interval for 120 mins by fluorescence assay2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID1701381Inhibition of human liver Cathepsin D at 182 nM preincubated for 10 mins followed by substrate addition and further incubated for 2 hrs in dark by fluorimetric analysis relative to control
AID415649Inhibition of HCV protease by fluorometric method2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Synthesis of dammarane-type triterpene derivatives and their ability to inhibit HIV and HCV proteases.
AID1409613Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID239204Inhibitory binding affinity towards synthesized human T-cell leukemia virus type I (HTLV-1) protease2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
AID156733Inhibitory activity was evaluated against pepsin using porcine pepsin (sigma), porcine hemoglobin (sigma) and 0.02 M KCl-HCl buffer (pH 2)1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors.
AID198470Inhibition of human plasma renin1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.
AID462227Antifungal activity against pharmacoresistant Candida albicans AIDS68 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 1 hr after fungal infection measured within 1 day of infe2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID448176Inhibition of cathepsin D2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID350740Inhibition of human liver cathepsin D after 30 mins by fluorometric end-point assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity.
AID294655Inhibition of hemoglobin hydrolysis in mouse erythrocytes at 5 mM after 18 hrs relative to control2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthesis and evaluation of sulfonylurea derivatives as novel antimalarials.
AID1409611AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID462242Antifungal activity against Candida albicans SA40 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 1 hr after fungal infection measured on day 1 after infection2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID47838Inhibitory activity was evaluated against bovine cathepsin D (sigma)1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors.
AID381968Antiparasitic activity against Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) after 18 hrs as reduced hemoglobin proteolysis2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis, antimalarial activity, structure-activity relationship analysis of thieno-[3,2-b]benzothiazine S,S-dioxide analogs.
AID160613Inhibition of recombinant HIV-1 protease1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease.
AID351542Inhibition of HIV1 protease by Hanes method2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
On the inhibition of HIV-1 protease by hydrazino-ureas displaying the N-->C=O interaction.
AID1701377Inhibition of Cathepsin D (unknown origin)
AID282104Inhibition of Leishmania donovani cysteine protease2004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.
AID340320Inhibition of HIV1 protease2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID427596Inhibition of SAP1-dependent growth in Candida albicans SAP2MS4B expressing SAP1ex4A at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID156736Tested for inhibition of pepsin from porcine1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
AID448193Selectivity ratio of IC50 for cathepsin E in human MCF7 cells treated for 1 hr measured after washout and trypsin treatment to IC50 for cathepsin E in human MCF7 cells2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID448185Selectivity ratio of IC50 for cathepsin D in human MCF7 cells to IC50 for cathepsin D2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID462239Antifungal activity against Candida albicans SA40 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 7 after infection2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID1529192Cytotoxicity against human PBMC cells assessed as reduction in cell viability up to 100 uM measured after 72 hrs by Celltiter-glo assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure-Activity Relationship and Binding Mode Analysis.
AID1493096Inhibition of secreted cathepsin E in human MDA-MB-231 cells using Mca-Gly-Lys-Pro-Ile-Leu-PhePhe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate pretreated for 3 days under pH 6.6 conditioned media followed by substrate addition measured at 5 mins interval for 2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID1529188Inhibition of human placenta CatD using Abz-Lys-Pro-Ala-Glu-Phe-Nph-Ala-Leu as substrate preincubated for 10 mins followed by substrate addition and measured by FRET assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure-Activity Relationship and Binding Mode Analysis.
AID1493104Cytotoxicity against human MDA-MB-231 cells assessed as effect on cell viability up to 10 uM after 72 hrs under pH 6.6 conditioned media by MTT assay2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID48010Inhibitory activity against human liver Cathepsin D using Cathepsin D assay.1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors.
AID1189198Inhibition of wild-type HIV-1 protease using fluorogenic peptide substrate incubated for 30 mins prior to substrate addition measured after 10 mins by FRET assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.
AID386435Inhibition of DPAP1 assessed as blocking of release of beta-naphthylamine from Ala-Pro-Ala-betaNA substrate at 1 uM2007The Journal of biological chemistry, Dec-07, Volume: 282, Issue:49
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
AID156757Inhibition of porcine pepsin1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.
AID335211Inhibition of Candida albicans secreted aspartic protease2002Journal of natural products, Jun, Volume: 65, Issue:6
New sesquiterpenoids from the root of Guatteria multivenia.
AID278816Antimalarial activity against Plasmodium falciparum D102007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID278818Antimalarial activity against Plasmodium falciparum Dd22007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID1740299Inhibition of recombinant Candida albicans SAP2 at 100 uM using Dabcyl-Arg-Lys-Pro-Ala-Leu-Phe-Phe-Arg-Leu-Glu (EDANS)-Arg-OH as substrate incubated for 30 mins followed by substrate addition and measured after 30 mins by spectrophotometry relative to con2020European journal of medicinal chemistry, Sep-01, Volume: 201Targeting fungal virulence factor by small molecules: Structure-based discovery of novel secreted aspartic protease 2 (SAP2) inhibitors.
AID1493093Inhibition of cathepsin E in human MDA-MB-231 cells using Mca-Gly-Lys-Pro-Ile-Leu-PhePhe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate pretreated for 4 hrs followed by compound washout and subsequent substrate addition measured at 30 secs interval for 30 mins 2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID357963Inhibition of Candida albicans ATCC 10231 secreted aspartic protease2001Journal of natural products, Oct, Volume: 64, Issue:10
Phenolic compounds from Miconia myriantha inhibiting Candida aspartic proteases.
AID225411In vitro inhibitory activity against hog plasma renin1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Pepstatin analogues as novel renin inhibitors.
AID47827Compound was tested for inhibition of bovine cathepsin D1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues.
AID1901891Inhibition of Cathepsin E (unknown origin) using Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate incubated for 120 mins by fluorescence assay2022Bioorganic & medicinal chemistry, 03-01, Volume: 57Cathepsin D inhibitors based on tasiamide B derivatives with cell membrane permeability.
AID351541Inhibition of HIV1 protease by Lineweaver-Burke method2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
On the inhibition of HIV-1 protease by hydrazino-ureas displaying the N-->C=O interaction.
AID198696Tested for inhibition of renin from human1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
AID47824Inhibition of bovine cathepsin D1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.
AID427592Inhibition of SAP4-dependent growth in Candida albicans SAP2MS4B expressing SAP4ex4A at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID278817Antimalarial activity against Plasmodium falciparum FAC82007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID396979Antimalarial activity as inhibition of chloroquine-resistant Plasmodium falciparum mediated mice (Mus musculus) hemoglobin hydrolysis at 5 mM after 18 hrs2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis of chlorovinyl sulfones as structural analogs of chalcones and their antiplasmodial activities.
AID331709Inhibition of human cathepsin D by FRET assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
AID580316Antimalarial activity against chloroquine-susceptible Plasmodium berghei ANKA assessed as inhibition of trophozoite extract-mediated mouse hemoglobin hydrolysis at 10 mM after 18 hrs by SDS-PAGE2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Synthesis and biological evaluation of benzimidazole-5-carbohydrazide derivatives as antimalarial, cytotoxic and antitubercular agents.
AID448192Selectivity ratio of IC50 for cathepsin D in human MCF7 cells treated for 1 hr measured after washout and trypsin treatment to IC50 for cathepsin D in human MCF7 cells2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID397592Therapeutic index, ratio of cytotoxicity against human H9 cells to EC50 for HIV1 RF2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID195626Inhibition of Renin1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.
AID1529190Apparent permeability in human Caco2 cells at 5 uM measured after 5 hrs by LC-MS analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure-Activity Relationship and Binding Mode Analysis.
AID1493092Inhibition of cathepsin D in human MDA-MB-231 cells using Mca-Gly-Lys-Pro-Ile-Leu-PhePhe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate pretreated for 4 hrs followed by compound washout and subsequent substrate addition measured at 30 secs interval for 30 mins 2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID1186402Inhibition of pepsin (unknown origin)2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Structure-based optimization of non-peptidic Cathepsin D inhibitors.
AID462224Antifungal activity against pharmacoresistant Candida albicans AIDS68 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 5 after inf2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID157638In vitro inhibitory activity against human plasma renin1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Pepstatin analogues as novel renin inhibitors.
AID448177Inhibition of cathepsin E2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID1189199Inhibition of multidrug resistant HIV-1 protease L10I/L63P/A71V/G73S/I84V/L90M mutant using fluorogenic peptide substrate incubated for 30 mins prior to substrate addition measured after 10 mins by FRET assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.
AID1184416Inhibition of HIV-1 protease using DABCYL-Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS as substrate preincubated at 1 uM for 15 mins before substrate addition measured over 15 mins by fluorometric assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors.
AID462223Antifungal activity against pharmacoresistant Candida albicans AIDS68 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 7 after inf2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID251721Inhibition of hemoglobin hydrolysis in mice (Mus musculus) infected with Plasmodium berghei at 10 uM2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives.
AID427595Inhibition of SAP2-dependent growth in Candida albicans SAP2MS4B expressing sap2delta mutant at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID361092Inhibition of Candida albicans secreted aspartic protease2002Journal of natural products, Jul, Volume: 65, Issue:7
Natural products inhibiting Candida albicans secreted aspartic proteases from Lycopodium cernuum.
AID1123541Inhibition of porcine pepsin activity assessed as hydrolysis of 0.5% hemoglobin solution substrate after 1 hr1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of all the stereoisomers of statine (4-amino-3-hydroxy-6-methylheptanoic acid). Inhibition of pepsin activity by N-carbobenzoxy-L-valyl-L-valyl-statine derived from the four stereoisomers.
AID462237Antifungal activity against Candida albicans SA40 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 21 after infection2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID427591Inhibition of SAP5-dependent growth in Candida albicans SAP2MS4B expressing SAP5ex4A at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID1186404Inhibition of cathepsin E (unknown origin)2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Structure-based optimization of non-peptidic Cathepsin D inhibitors.
AID44257Compound (>1 mM ) was tested for inhibition of Beta-secretase 1 (BACE 1) expressed in insect cell using baculovirus; Not inhibited2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Rational design and synthesis of selective BACE-1 inhibitors.
AID427594Inhibition of SAP2-dependent growth in Candida albicans SAP2MS4B expressing SAP2ex4A at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID225409In vitro inhibitory activity against monkey plasma renin1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Pepstatin analogues as novel renin inhibitors.
AID448188Inhibition of cathepsin D in human MCF7 cells treated for 1 hr measured after washout and trypsin treatment by fluorescence assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID427590Inhibition of SAP6-dependent growth in Candida albicans SAP2MS4B expressing SAP6ex4A at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID448183Inhibition of cathepsin D in human MCF7 cells by fluorescence assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID1493089Selectivity ratio of IC50 for human liver cathepsin D to IC50 for recombinant human C-terminal His10-tagged cathepsin E (Gln18 to Pro396 residues)2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID198468Compound was evaluated for the ability to inhibit human plasma renin.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.
AID448189Inhibition of cathepsin E in human MCF7 cells treated for 1 hr measured after washout and trypsin treatment by fluorescence assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID160777Binding affinity to HIV-1 protease1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Three-dimensional pharmacophores from binding data.
AID462226Antifungal activity against pharmacoresistant Candida albicans AIDS68 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 1 hr after fungal infection measured on day 1 after infec2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID1305442Inhibition of human recombinant cathepsin E using Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 120 mins by fluorescence analysis2016Bioorganic & medicinal chemistry, 08-01, Volume: 24, Issue:15
Tasiamide F, a potent inhibitor of cathepsins D and E from a marine cyanobacterium.
AID480879Inhibition of Plasmodium falciparum plasmepsin-2 expressed in Escherichia coli BL21 (DE3) at 1 uM after 1 to 2 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
AID198676Inhibitory activity against human renin1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel inhibitors of human renin. Cyclic peptides based on the tetrapeptide sequence Glu-D-Phe-Lys-D-Trp.
AID1305441Inhibition of human liver cathepsin D using Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 120 mins by fluorescence analysis2016Bioorganic & medicinal chemistry, 08-01, Volume: 24, Issue:15
Tasiamide F, a potent inhibitor of cathepsins D and E from a marine cyanobacterium.
AID271447Inhibition of human cathepsin D2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Synthesis of gallic acid based naphthophenone fatty acid amides as cathepsin D inhibitors.
AID1493088Inhibition of recombinant human C-terminal His10-tagged cathepsin E (Gln18 to Pro396 residues) using Mca-Gly-Lys-Pro-Ile-Leu-PhePhe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate pretreated for 15 mins followed by substrate addition measured at 5 mins interval 2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID199015In vitro inhibitory activity towards porcine kidney renin1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
AID448191Selectivity ratio of IC50 for cathepsin E in human MCF7 cells treated for 1 hr measured after washout and trypsin treatment to IC50 for cathepsin E2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID462236Antifungal activity against Candida albicans SA40 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 28 after infection2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID243926Percent inhibition of recombinant human T-cell leukemia virus type I (HTLV-1) protease was determined at 50 uM concentration2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
AID427589Inhibition of SAP8-dependent growth in Candida albicans SAP2MS4B expressing SAP8ex4A at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID1409608AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID198818Inhibition of human plasma renin1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.
AID462243Antifungal activity against Candida albicans SA40 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 1 hr after fungal infection measured within 1 day of infection2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID1409609Cytotoxicity of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1493106Inhibition of cathepsin D in human MDA-MB-231 cells assessed as increase in secreted PAI-1 level up to 100 uM after 3 days under pH 6.6 conditioned media by ELISA2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID350737Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity.
AID397608Inhibition of HIV1 protease expressed in Escherichia coli2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID198668Inhibitory activity against human plasma renin at pH 7.41989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue.
AID343512Inhibition of recombinant HIV1 protease2008Journal of natural products, Jun, Volume: 71, Issue:6
Anti-HIV-1 protease activity of lanostane triterpenes from the vietnamese mushroom Ganoderma colossum.
AID1305443Selectivity ratio of IC50 for human liver cathepsin D to IC50 for human recombinant cathepsin E2016Bioorganic & medicinal chemistry, 08-01, Volume: 24, Issue:15
Tasiamide F, a potent inhibitor of cathepsins D and E from a marine cyanobacterium.
AID448178Inhibition of ADAM92009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID462241Antifungal activity against Candida albicans SA40 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 24 hrs after fungal infection measured on day 2 after infection2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID156724Compound was measured for the inhibition of pepsin hydrolysis of hemoglobin.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
New pepstatin analogues: synthesis and pepsin inhibition.
AID1493097Inhibition of human liver cathepsin D at 5 uM using recombinant human cystatin-C as substrate measured after 3 hrs by silver staining based SDS-PAGE analysis2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID198678Inhibitory activity against purified human plasma renin at pH 6.01989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue.
AID427593Inhibition of SAP3-dependent growth in Candida albicans SAP2MS4B expressing SAP3ex4A at 7.3 uM incubated in YCB-BSA medium2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
AID581962Antimicrobial activity against leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
AID1493095Inhibition of cathepsin E in human MDA-MB-231 cells using Mca-Gly-Lys-Pro-Ile-Leu-PhePhe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate pretreated for 4 hrs followed by compound washout and subsequent 10 mins trypsinization prior to substrate addition measured 2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID1529189Solubility of the compound in pH 7.4 phosphate buffered saline by HPLC-MS analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure-Activity Relationship and Binding Mode Analysis.
AID448190Selectivity ratio of IC50 for cathepsin D in human MCF7 cells treated for 1 hr measured after washout and trypsin treatment to IC50 for cathepsin D2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
AID351540Inhibition of HIV1 protease by FRET assay2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
On the inhibition of HIV-1 protease by hydrazino-ureas displaying the N-->C=O interaction.
AID48184Binding affinity against Cathepsin D2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID1067634Inhibition of HIV-1 recombinant protease using DABCYL-GABA-Ser-Asn-Tyr-Pro-Ile-Val-Gln-EDANS as substrate incubated for 30 mins prior to substrate addition by Dixon plot analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.
AID462259Antifungal activity against pharmacoresistant Candida albicans AIDS68 infected in Wistar rat estrogen-dependent fungal vaginitis model assessed as fungal burden at 10 ug administered intravaginally 48 hrs after fungal infection measured on day 21 after in2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
AID156585Compound was evaluated for the ability to inhibit penicillopepsin.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.
AID350739Inhibition of human liver cathepsin H after 30 mins by fluorometric end-point assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity.
AID37935Tested for inhibition of Angiotensin I converting enzyme from rabbit.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
AID156895Inhibitory activity against pepsin as oxidation of o-phenylenediamine by Horse radish peroxidase (Pepsin sensitive)1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Auxiliary agents for the peroral administration of peptide and protein drugs: synthesis and evaluation of novel pepstatin analogues.
AID1493094Inhibition of cathepsin D in human MDA-MB-231 cells using Mca-Gly-Lys-Pro-Ile-Leu-PhePhe-Arg-Leu-Lys-(Dnp)-D-Arg-NH2 as substrate pretreated for 4 hrs followed by compound washout and subsequent 10 mins trypsinization prior to substrate addition measured 2017Journal of natural products, 11-22, Volume: 80, Issue:11
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
AID397607Antiviral activity against HIV1 Rojo in human CEM cells2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID1391981Inhibition of Plasmodium falciparum plasmepsin-1 using DABCYL-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-EDANS as substrate preincubated for 30 mins followed by substrate addition measured every 1 min within 8 to 15 mins by FRET assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity.
AID156765Compound was measured for the apparent inhibition constant at pepsin1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
New pepstatin analogues: synthesis and pepsin inhibition.
AID198512In vitro inhibitory activity against human plasma renin1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
AID1189200Selectivity ratio of Ki for multidrug resistant HIV-1 protease L10I/L63P/A71V/G73S/I84V/L90M mutant to Ki for wild-type HIV-1 protease2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1993Proceedings of the National Academy of Sciences of the United States of America, Jul-15, Volume: 90, Issue:14
Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design.
AID1795283Protease Inhibition Assay from Article 10.1021/jm00041a005: \\Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease.\\1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1811Experimentally measured binding affinity data derived from PDB1984FEBS letters, Aug-20, Volume: 174, Issue:1
The active site of aspartic proteinases.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1984FEBS letters, Aug-20, Volume: 174, Issue:1
The active site of aspartic proteinases.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1996Proceedings of the National Academy of Sciences of the United States of America, Sep-17, Volume: 93, Issue:19
Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.
AID1811Experimentally measured binding affinity data derived from PDB1996Proceedings of the National Academy of Sciences of the United States of America, Sep-17, Volume: 93, Issue:19
Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.
AID1811Experimentally measured binding affinity data derived from PDB1992Proteins, Jul, Volume: 13, Issue:3
Structures of complexes of rhizopuspepsin with pepstatin and other statine-containing inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1992Proteins, Jul, Volume: 13, Issue:3
Structures of complexes of rhizopuspepsin with pepstatin and other statine-containing inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (674)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990118 (17.51)18.7374
1990's203 (30.12)18.2507
2000's206 (30.56)29.6817
2010's125 (18.55)24.3611
2020's22 (3.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.81 (24.57)
Research Supply Index6.55 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index75.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews12 (1.72%)6.00%
Case Studies2 (0.29%)4.05%
Observational0 (0.00%)0.25%
Other682 (97.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]